Ghosh Sarbari, Sarkar Madhurima, Ghosh Tithi, Guha Ipsita, Bhuniya Avishek, Biswas Jaydip, Mallick Atanu, Bose Anamika, Baral Rathindranath
Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), 37, S.P. Mukherjee Road, Kolkata 700 026, India.
Department of Surgical Oncology and Medical Oncology, Chittaranjan National Cancer Institute (CNCI), 37, S.P. Mukherjee Road, Kolkata 700 026, India.
Immunol Lett. 2016 Jul;175:31-9. doi: 10.1016/j.imlet.2016.05.004. Epub 2016 May 10.
One of the prime objectives of cancer immunology and immunotherapy is to study the issues related to rescue and/or maintenance of the optimum effector CD8(+) T cell functions by minimizing tumor-induced negative factors. In this regard the influence of host intrinsic CD4(+) helper T cells towards generation and maintenance of CD8(+) effector T cells appears controversial in different experimental settings. Therefore, the present study was aimed to re-analyze the influence of CD4(+) helper T cells towards effector T cells during neem leaf glycoprotein (NLGP)-vaccine-mediated tumor growth restriction. CD4 depletion (mAb; Clone GK1.5) surprisingly resulted in significant increase in CD8(+) T cells in different immune organs from NLGP-treated sarcoma-bearing mice. However, such CD8 surge could not restrict the sarcoma growth in NLGP-treated CD4-depleted mice. Furthermore, CD4 depletion in early phase hinders CD8(+) T cell activation and terminal differentiation by targeting crucial transcription factor Runx3. CD4 depletion decreases accumulation of CD8α(+) dendritic cells within tumor draining lymph node, hampers antigen cross priming and CD86-CD28 interactions for optimum CD8(+) T cell functions. In order to search the mechanism of CD4(+) T cell help on NLGP-mediated CD8 effector functions, the role of CD4(+) helper T cell-derived IL-2 on optimization of CD8 functions was found using STAT5 signaling, but complete response requires physical contact of CD4(+) helper T cells with its CD8 counterpart. In conclusion, it was found that CD4(+) T cell help is not required to generate CD8(+) T cells but was found to be an integral phenomenon in maintenance of its anti-tumor functions even in NLGP-vaccine-mediated sarcoma growth restriction.
癌症免疫学和免疫疗法的主要目标之一是研究通过最小化肿瘤诱导的负面因素来拯救和/或维持最佳效应CD8(+) T细胞功能的相关问题。在这方面,宿主内在CD4(+)辅助性T细胞对CD8(+)效应性T细胞的产生和维持的影响在不同的实验环境中似乎存在争议。因此,本研究旨在重新分析印楝叶糖蛋白(NLGP)疫苗介导的肿瘤生长限制过程中CD4(+)辅助性T细胞对效应性T细胞的影响。令人惊讶的是,CD4耗竭(单克隆抗体;克隆GK1.5)导致NLGP处理的荷肉瘤小鼠不同免疫器官中CD8(+) T细胞显著增加。然而,这种CD8激增并不能限制NLGP处理的CD4耗竭小鼠中的肉瘤生长。此外,早期的CD4耗竭通过靶向关键转录因子Runx3阻碍CD8(+) T细胞活化和终末分化。CD4耗竭减少肿瘤引流淋巴结内CD8α(+)树突状细胞的积累,阻碍抗原交叉启动以及CD86-CD28相互作用以实现最佳的CD8(+) T细胞功能。为了探究CD4(+) T细胞辅助对NLGP介导的CD8效应功能的机制,利用STAT5信号通路发现CD4(+)辅助性T细胞衍生的IL-2对CD8功能优化的作用,但完全应答需要CD4(+)辅助性T细胞与其CD8对应细胞进行物理接触。总之,研究发现产生CD8(+) T细胞不需要CD4(+) T细胞辅助,但即使在NLGP疫苗介导的肉瘤生长限制中,CD4(+) T细胞辅助也是维持其抗肿瘤功能不可或缺的现象。